Generic Name and Formulations:
Midodrine HCl 2.5mg, 5mg, 10mg; scored tabs.
Various generic manufacturers
Indications for Midodrine:
Symptomatic orthostatic hypotension.
Take during the day while upright; allow at least 4 hours between last dose and bedtime. 10mg 3 times daily at 3–4 hour intervals. Renal dysfunction: initially 2.5mg 3 times daily. Discontinue if no improvement after initial therapy.
Severe heart disease. Acute renal disease. Urinary retention. Pheochromocytoma. Thyrotoxicosis. Persistent, excessive supine hypertension.
Initial supine systolic pressure >180mmHg: not recommended. Monitor supine and sitting BP. Discontinue if supine hypertension occurs. Diabetes. Renal or hepatic impairment. Pregnancy (Cat.C). Nursing mothers.
Avoid concomitant drugs that increase BP (eg, phenylephrine, pseudoephedrine, ephedrine, dihydroergotamine, thyroid hormones, droxidopa); if unavoidable, monitor BP closely. Avoid concomitant MAO inhibitors or linezolid. Potentiated by sodium-retaining steroids (eg, fludrocortisone acetate); caution in increased intraocular pressure with fludrocortisone. Antagonized by α-antagonists (eg, prazosin, terazosin, doxazosin). Levels may be affected by renally-excreted alkaline drugs (eg, metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, quinidine). Cardiac glycosides, β-blockers, CNS drugs may cause bradycardia, AV block, arrhythmias; discontinue if bradycardia occurs.
Paresthesia, piloerection, dysuria, pruritus, supine hypertension, chills, pain, rash.
Formerly known under the brand name Proamatine.
Endocrinology Advisor Articles
- Subclinical Hypothyroidism: Controversies in Testing and Treatment
- Favorable Outcomes With Second-Generation Insulin Analogs in Type 2 Diabetes
- Type 2 Diabetes and Alzheimer Disease: What's the Connection?
- Canagliflozin Trial for T2D With CKD Stopped Early Due to Positive Results
- Treatment With Alemtuzumab May Frequently Induce Thyroid Dysfunction
- Using Latent Class Trajectory Analysis to Determine Glucose Response Curve Patterns
- First CGM System With Implantable Glucose Sensor Approved
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Risk for Below Knee Amputations With Canagliflozin vs Other Antihyperglycemic Agents
- Two Phases of C-Peptide Decline Identified in Type I Diabetes
- Effect of SGLT2 Inhibitors on Heart Failure-Related Hospitalization, Below-Knee Amputation
- Nutraceuticals Containing Equol May Be Effective for Postmenopausal Symptoms
- Conservative Monitoring Strategy for Non-Functioning Pituitary Adenomas Evaluated
- FDA: Some Rx Drugs May Become Available Without Seeing a Doctor
- PM2.5 Contributes to Burden of Diabetes Mellitus Globally